Canada does not prescribe a single set of laboratory or clinical tests that every cosmetic must complete before sale. Instead, manufacturers and importers of skincare brands are responsible for ensuring that their cosmetics are safe under the applicable conditions of use and that their marketing claims are properly supported. The testing and evidence needed will therefore depend on the formulation, intended use, product claims, and information already available.
For manufacturers and importers, the distinction has practical consequences. A supplier dossier, a favourable patch test and a completed Cosmetic Notification Form (CNF) each serve a different purpose; none should be treated as a complete demonstration of product readiness on its own. An effective cosmetic testing strategy connects the available information to the finished product, identifies unresolved questions, and directs further work towards the evidence that matters for Canadian market entry.
At a Glance
- No universal testing panel
- Safety is mandatory
- Notification is not approval
- Health Canada can request safety evidence
- Claims need substantiation
- Testing should be risk- and claim-based
- Understanding Cosmetic Testing Requirements in Canada
- Product Classification and Formulation Determine the Testing Strategy
- Selecting Cosmetic Safety and Stability Testing
- Connecting Cosmetic Claims With Appropriate Evidence
- Maintaining Cosmetic Safety Documentation Through Product Changes
- Bringing the Testing Plan Into the Launch Decision
- Final Remarks
- FAQ
Understanding Cosmetic Testing Requirements in Canada
The Food and Drugs Act establishes the underlying safety obligation. Section 16 prohibits the sale of cosmetics containing substances that may injure users when used as directed or in the customary manner. It also prohibits cosmetics containing specified objectionable matter and those manufactured, prepared, preserved, packaged, or stored under unsanitary conditions. These provisions apply regardless of production volume, making safety assessment relevant to an emerging skincare brand as well as an established manufacturer expanding its portfolio.
The obligation to support safety continues after launch. Under section 29 of the Cosmetic Regulations, Health Canada may request evidence establishing a cosmetic’s safety under recommended or normal conditions of use. A manufacturer or importer that misses the specified submission deadline must cease selling the product on the following day. If the submitted evidence is found insufficient, sales must stop until further evidence has been provided and Health Canada has confirmed in writing that it is sufficient. Maintaining an organized, current evidence file therefore helps demonstrate that appropriate safety considerations have been addressed and supports the manufacturer or importer’s ability to respond to regulatory scrutiny.
Cosmetic notification is a separate obligation. Manufacturers and importers must notify Health Canada within 10 days after first selling a cosmetic in Canada, but submission of a CNF does not constitute approval, confirmation of classification, or acceptance of the product’s compliance. The filing deadline should consequently be treated as an administrative requirement, not an opportunity to establish safety after consumers have begun using the product.
The notification deadline is therefore not simply a filing formality. Under the Cosmetic Regulations, a cosmetic cannot continue to be sold after the applicable 10-day period if the required notification has not been provided.
Product Classification and Formulation Determine the Testing Strategy
Before selecting cosmetic safety testing, a brand should establish that the product belongs within the cosmetic regulatory framework.
Health Canada’s cosmetic–drug classification guidance considers factors including composition and representation. A cream promoted to improve skin appearance raises different questions from one represented as treating eczema or healing wounds, while products making SPF or sunblock claims are not treated as ordinary cosmetics.
Evidence supporting a therapeutic effect does not, by itself, make that claim permissible on a cosmetic. Resolving classification early helps ensure that testing addresses the appropriate regulatory pathway.
Within the cosmetic category, ingredient review should extend beyond checking whether a substance appears on the Cosmetic Ingredient Hotlist. The Hotlist communicates restrictions and prohibitions for certain cosmetic ingredients, but an ingredient’s absence from the Hotlist does not, by itself, establish the safety of the finished formulation. A meaningful assessment must also consider ingredient concentrations, the way ingredients are used together, the intended area and frequency of application, and other relevant exposure conditions.
For example, a leave-on product applied around the eyes presents different considerations from a cleanser rinsed off after brief contact. As a practical planning step, reviewing the complete formulation alongside ingredient specifications, supplier evidence, and intended use allows a qualified assessor to distinguish supported aspects of the product from areas requiring further investigation. This provides a reasoned basis for commissioning additional work and reduces the likelihood of discovering material evidence gaps late in development.
Selecting Cosmetic Safety and Stability Testing
Cosmetic safety testing should address the risks identified during product assessment. The appropriate combination of microbiological evaluation, stability work, and human testing will depend on the formulation and its use; the methods discussed below are not a mandatory Canadian test panel. Their value lies in answering specific questions that cannot be resolved adequately through the information already available.
Microbiological Quality and Preservative Efficacy Testing
Once ingredient suitability has been assessed, the next consideration is whether the finished formulation is adequately protected against microbial contamination during manufacture, storage and consumer use. Microorganisms can enter a product through contaminated raw materials, production equipment, packaging or handling after opening. The formulation preservation system must therefore be considered alongside manufacturing and packaging controls when assessing microbiological safety.
Preservative efficacy testing, commonly called challenge testing, helps assess whether the formulation preservation system can control microorganisms under defined conditions. ISO 11930:2019 provides a framework for evaluating antimicrobial protection of cosmetic products through preservative efficacy testing and, where applicable, microbiological risk assessment. Products determined to be microbiologically low risk under ISO 29621 may not require application of the preservation efficacy test. The need for challenge testing should be determined through a documented assessment of the finished product, including whether it qualifies as microbiologically low risk. These findings inform the overall safety assessment but do not replace the manufacturing, packaging, and handling controls needed to prevent contamination.
Cosmetic Stability Testing and Packaging Compatibility
Alongside microbiological protection, brands must consider whether the finished product will maintain its quality throughout its intended shelf life. A formulation that meets its initial specifications immediately after manufacture may change during transportation, storage, or repeated use.
Cosmetic stability testing evaluates these changes under defined conditions, using measurements selected according to the formulation’s characteristics and potential vulnerabilities. For example, an emulsion may require monitoring for separation or changes in viscosity, while other formulations may warrant particular attention to pH, colour, or odour. The packaging should also be included in this assessment because it can affect the product’s exposure to air, moisture and light, and may interact with the formulation itself. Testing should therefore reflect the formulation and packaging combination intended for sale.
These differences between products explain why a single stability protocol cannot establish an appropriate shelf life for every cosmetic. ISO/TR 18811 provides a technical framework for developing a stability assessment but leaves the manufacturer responsible for specifying and justifying the test conditions, measurements, and acceptance criteria. The protocol should connect the changes being monitored with the conditions the product is expected to encounter. This allows the results to inform decisions about shelf life, storage instructions and packaging suitability. Before relying on those results for launch, brands should understand what the study demonstrates, where uncertainty remains, and whether further monitoring is needed to confirm the proposed shelf life.
Human Skin Compatibility Testing
While microbiological and stability assessments help establish whether a formulation remains suitable for use, they do not directly show how the skin will respond to its application. Where appropriate, human skin compatibility testing can help address this question by evaluating irritation and tolerability under controlled conditions.
Before exposing participants to the product, the available safety information should be reviewed to determine whether the proposed testing is appropriate. The protocol should then account for how the product will be applied, how long it will remain in contact with the skin, and which population will be assessed.
A cleanser intended to be rinsed off, for example, requires different exposure considerations from a leave-on cream, as discussed in SNI’s guidance on rinse-off cosmetic testing. These study conditions also define the limits of the findings: favourable results provide evidence of tolerability under the circumstances assessed, but cannot guarantee that every consumer will use the product without experiencing a reaction.
The distinction between what a study evaluates and what its results support also matters when describing the testing on a label or in advertising. Health Canada explains that “dermatologist-tested” refers to irritation testing involving a skin doctor at some point during the study. The term does not establish that the product delivers its advertised benefits, and Canadian regulations do not standardize the number or type of tests required to use it.
Brands should therefore retain records explaining the testing performed, the findings, and the dermatologist’s involvement. This documentation provides a basis for assessing whether the claim accurately represents the study without implying broader safety or efficacy conclusions.
Connecting Cosmetic Claims With Appropriate Evidence
Once product safety and tolerability have been assessed, brands must consider whether separate evidence is needed to support the benefits they intend to advertise. A study evaluating skin irritation, for example, does not establish that a moisturizer provides lasting hydration or improves the appearance of fine lines. Those claims require evidence that addresses the stated benefit.
Under paragraph 74.01(1)(b) of the Competition Act, claims concerning performance, effectiveness, or length of life must be based on an adequate and proper test conducted before the claim is made. The Competition Bureau’s guidance also considers the general impression conveyed by advertising. Brands must therefore assess whether their evidence supports both the wording of a claim and the message communicated through accompanying images and presentation. This is a separate obligation from the product-safety requirements under the Food and Drugs Act and Cosmetic Regulations.
Because the proposed benefit determines what needs to be measured, claim development should begin before testing is commissioned. For example, participants reporting that their skin feels more hydrated provide different evidence from instrumental measurements showing a change in skin hydration. Either may contribute useful findings, but the resulting claims must accurately reflect the method used and the outcome assessed.
Final claim wording should therefore be reviewed against the study results and limitations before it appears on packaging, websites, or promotional materials. Our article on skincare clinical trials and cosmetic claim substantiation explores this interpretation in greater detail. For market readiness, the practical decision is whether the available evidence supports the proposed claim, whether the wording needs to be narrowed, or whether additional testing is required.
Maintaining Cosmetic Safety Documentation Through Product Changes
Once the available evidence has been assessed, brands should document how it supports the finished product and its safety conclusions. Canada does not require an EU-style Cosmetic Product Safety Report for cosmetics, but Health Canada can request safety evidence under the Cosmetic Regulations.
Maintaining an organized file helps manufacturers and importers respond to such requests by linking ingredient information, specifications, and test results to the formulation, packaging, and intended use. The documentation should explain the basis for the safety conclusions and identify any limitations, allowing a reviewer to determine whether the evidence applies to the product currently being sold.
This connection becomes particularly important when a product changes. Replacing a preservative, switching ingredient suppliers, or introducing different packaging may affect the original safety assessment.
For example, evidence generated for a formulation in a pump dispenser may require reassessment if the product is subsequently sold in a jar that allows direct contact during use.
Changes should therefore be reviewed to determine whether existing evidence remains applicable and whether additional testing is warranted. Consumer complaints and new safety information should also prompt reassessment where they raise questions about previous conclusions.
Brands must also consider whether the data can be used to establish safety under Canadian law. Canada’s cosmetic animal testing restrictions, effective December 22, 2023, prohibit specified testing and restrict the sale of cosmetics whose safety relies on prohibited animal testing data, subject to statutory exceptions. Historical studies and supplier reports should therefore be assessed for both relevance to the current product and permissibility under these provisions.
Where a brand claims that its cosmetic has not been tested on animals, the claim must also be substantiated. Keeping supporting records alongside the safety assessment helps demonstrate why the evidence is appropriate and how any related claims are supported.
Bringing the Testing Plan Into the Launch Decision
Once the evidence has been reviewed and documented, the next step is determining whether any unresolved findings affect the product’s readiness for sale. As a practical quality and launch-management step, each outstanding assessment should have a defined purpose, with responsibility assigned for interpreting the results and deciding what action they require.
For example, an unresolved stability concern may require changes to the formulation or packaging, while insufficient support for a performance claim may require additional testing or narrower wording.
Identifying these possibilities during planning allows the brand to account for potential revisions in its launch schedule and distinguish work needed for regulatory compliance from additional retailer requirements or commercial objectives.
The final review should confirm that the evidence applies to the formulation and packaging being released, supports the intended use, and justifies the claims that consumers will encounter. Addressing cosmetic testing requirements in Canada therefore involves evaluating what the results establish and resolving material gaps before proceeding with sale. Documenting this decision provides a clear basis for launch and a reference against which future product changes or new safety information can be assessed.
Final Remarks
Cosmetic testing requirements in Canada do not prescribe the same set of laboratory tests or clinical studies for every skincare product. Manufacturers and importers must ensure that their cosmetics are safe under recommended or normal conditions of use, while performance claims must be supported by adequate and proper testing conducted before those claims are made. The appropriate testing program therefore depends on the finished formulation, packaging, intended use, and proposed representations.
Clinical studies become particularly important when a proposed benefit requires evidence of how the finished product performs on human skin. Claims such as providing hydration for a specified duration or visibly reducing the appearance of wrinkles may require controlled human studies when ingredient literature and laboratory assessments cannot adequately substantiate the advertised outcome. In these circumstances, the study must evaluate the relevant benefit under conditions that support the proposed wording. This does not make clinical trials universally mandatory for cosmetics; it makes the evidence requirements specific to the claim.
For skincare brands, meeting these obligations begins with reviewing the available evidence and identifying where further assessment is needed. Each test should address a defined question relevant to product safety or performance. Maintaining the resulting documentation, and reassessing it when the product changes, provides a defensible basis for Canadian market entry and continued sale.
How SNI Clinical Research Can Support Your Skincare Testing Strategy
When you need to determine what testing is appropriate for a skincare product, SNI Clinical Research can help connect your product claims with adequate study objectives, endpoints, and testing approach. Our team can review your available evidence and develop a clinical testing approach that addresses the outcomes you intend to communicate, with consideration for the product’s intended use and target population. This helps ensure that the research generates relevant findings and that the resulting claims reflect what the study demonstrates.
Whether you are developing a new skincare product or strengthening the evidence behind an established formulation, share your product information and proposed claims with SNI Clinical Research to discuss the next steps. Explore our skincare clinical testing services or contact our team to determine an appropriate scope for your project.
As product technologies evolve and regulatory expectations continue to rise, PK/PD evidence has become essential rather than optional. Applying these principles early strengthens development decisions, reduces uncertainty, and supports predictable, defensible pathways to approval.
Send us a request for an introductory call using the form below!
FAQ
Is Clinical Testing Mandatory for Every Cosmetic in Canada?
No. Canada does not impose a universal requirement for every cosmetic to undergo a human clinical efficacy trial. Product safety obligations still apply, and performance claims require adequate and proper testing. The appropriate evidence depends on the formulation, intended use and representations made about the product.
Does Cosmetic Notification Confirm (CNF) That a Product Is Safe?
No. A CNF does not constitute Health Canada approval or confirmation of safety, classification or compliance. Manufacturers and importers remain responsible for meeting the applicable requirements, independently of notification.
Does Every Skincare Product Need Preservative Efficacy Testing?
The decision should follow a microbiological risk assessment. ISO 11930:2019 distinguishes products assessed as microbiologically low risk from those requiring evaluation under its preservation framework. A decision not to conduct challenge testing should have a documented technical basis relevant to the finished product.
Do Cosmetics Require a Cosmetic Product Safety Report in Canada?
An EU-style Cosmetic Product Safety Report is not a general Canadian cosmetic requirement. However, manufacturers and importers should maintain appropriate evidence supporting safety and be prepared to respond to a request under section 29 of the Cosmetic Regulations.
Can Health Canada Request Safety Evidence After a Product Is Launched?
Yes. Section 29 permits written requests for evidence establishing safety under recommended or normal conditions of use. Missing the specified deadline or providing evidence found insufficient can require sales to stop under the conditions set out in that section.
What Testing is Required Before Selling a Cosmetic in Canada?
Canada does not prescribe a universal pre-market testing package for all cosmetics, Manufacturers and importers must ensure that the product complies with applicable requirements and is safe under recommended or normal conditions of use. The appropriate testing and supporting evidence depend on the formulation, intended use, exposure, microbiological risk, packaging, and claims. Health Canada may also request evidence establishing safety under section 29 of the Cosmetic Regulations.
✷ The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.